Targeting EGFR in patients with non-small-cell lung cancer (NSCLC) in addition to chemotherapy might provide survival benefits in patients with EGFR-positive tumors. Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525–1531 (2009).
Rosell, R. et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19, 362–369 (2008).
Lynch, T. J. et al. Overall survival (OS) results from the phase III trial BMS 099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. J. Thorac. Oncol. 3, S305 (2008).
Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).
Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25, 1545–1552 (2007).
Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417 (2009).
Tsao, M. S. et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).
Eberhard, A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900–5909 (2005).
Khambata-Ford, S. et al. K-RAS mutations and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS-099 study. J. Thorac. Oncol. 3, S304 (2008).
Gatzemeter, V. et al. FLEX: cetuximab in combination with platinum-based chemotherapy improves survival versus CT alone for NSCLC. J. Thorac. Oncol. 3, S265 (2008).
Dr. David Kerr is on the Speakers bureau at Merk KGA. Dr. Rasul declares no competing interests.
About this article
Cite this article
Rasul, K., Kerr, D. Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol 6, 499–500 (2009). https://doi.org/10.1038/nrclinonc.2009.108
Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC
Oncology Letters (2016)
Frontiers in Immunology (2014)
Nature Reviews Clinical Oncology (2014)
CA: A Cancer Journal for Clinicians (2012)
Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Journal of Clinical Oncology (2010)